Most insurance plans that cover weight loss injections limit coverage to two FDA-approved medications: semaglutide (Wegovy) and tirzepatide (Zepbound). Whether your specific plan covers them depends on your insurance type, your BMI, and whether you meet additional medical criteria. Only 19% of large employers currently cover GLP-1 medications for weight loss, and Medicare won’t begin covering them for that purpose until mid-2026.
FDA-Approved Weight Loss Injections
Four injectable medications are FDA-approved for chronic weight management, but only two are widely relevant for insurance coverage purposes:
- Semaglutide (Wegovy): a once-weekly injection, the most commonly covered weight loss injectable
- Tirzepatide (Zepbound): a once-weekly injection, newer but increasingly included on formularies
- Liraglutide (Saxenda): a daily injection, older and less commonly prescribed now
- Setmelanotide (IMCIVREE): a daily injection approved only for people with specific rare genetic disorders confirmed by testing
You may have heard of Ozempic and Mounjaro in the context of weight loss. These contain the same active ingredients as Wegovy and Zepbound, respectively, but they are only FDA-approved for type 2 diabetes. Insurers almost never cover Ozempic or Mounjaro for weight loss alone. If your doctor prescribes one of these off-label for obesity without a diabetes diagnosis, expect to pay out of pocket.
Standard BMI and Medical Requirements
Nearly every insurer uses the same baseline criteria, which mirror the FDA label. You typically qualify if you meet one of these thresholds:
- BMI of 30 or higher with no additional conditions required
- BMI of 27 or higher with at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol
For adolescents aged 12 to 17, some plans require a BMI of 30 or above along with a minimum body weight of about 132 pounds (60 kg). Your BMI at the time you start the medication is what counts, not a historical number.
Prior Authorization: What to Expect
Almost no insurer covers weight loss injections without prior authorization. This means your doctor needs to submit paperwork proving you meet the plan’s criteria before the pharmacy will fill your prescription. The process typically takes a few days to a few weeks.
Many plans require documentation that you’ve already tried losing weight through other means. Some state employee plans, for example, require participation in a comprehensive weight management program for at least six months before approving drug therapy. This program generally needs to include dietary changes, increased physical activity, behavioral counseling, and follow-up visits. If your insurer has this requirement and you haven’t completed it, your prior authorization will be denied regardless of your BMI.
Your doctor’s office handles most of the paperwork, but you can speed the process along by confirming your plan’s specific requirements before the first appointment. Call the number on the back of your insurance card and ask whether weight loss injectables are on your formulary and what prior authorization steps apply.
Employer-Sponsored Insurance
Coverage through employer plans remains uncommon. As of 2025, only about 19% of employers with 200 or more employees cover GLP-1 medications for weight loss. That means roughly four out of five people with employer-sponsored insurance don’t have this benefit at all.
When employers do offer coverage, they frequently add their own restrictions on top of the standard BMI criteria. These can include step therapy (requiring you to try a cheaper medication first), quantity limits, or annual re-authorization that requires you to show a minimum amount of weight loss to continue receiving the drug. Some employers cover Wegovy but not Zepbound, or vice versa, so checking your specific formulary matters.
Medicare Coverage
Medicare has historically excluded weight loss drugs from Part D coverage. That is changing, but slowly. A new program called the Medicare GLP-1 Bridge will provide coverage from July 1, 2026, through December 31, 2027. It is a short-term demonstration, not a permanent benefit.
The eligibility criteria for the Bridge program are more specific than typical commercial insurance. You must meet one of three tiers:
- BMI of 35 or higher: no additional diagnosis required
- BMI of 30 or higher: plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled high blood pressure despite taking two medications, or chronic kidney disease stage 3a or above
- BMI of 27 or higher: plus a history of heart attack, stroke, symptomatic peripheral artery disease, or pre-diabetes
There’s an important exception. If you qualify for a GLP-1 under a use that Medicare Part D already covers, you won’t go through the Bridge program. Wegovy is already coverable under Part D to reduce cardiovascular risk in adults with established heart disease and obesity or overweight. Zepbound is coverable for moderate to severe obstructive sleep apnea in adults with obesity. If either of those applies to you, your Part D plan handles coverage through its existing formulary and exception process right now.
Medicaid Coverage
Medicaid coverage for weight loss injections varies dramatically by state. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity treatment under fee-for-service. Coverage for GLP-1s prescribed for diabetes, cardiovascular disease, or sleep apnea is required in all states, but coverage specifically for obesity remains optional.
The landscape is shifting and not always in the direction of more coverage. Four states (California, New Hampshire, Pennsylvania, and South Carolina) eliminated Medicaid coverage for obesity-related GLP-1 prescriptions between October 2025 and January 2026. North Carolina dropped coverage briefly due to a budget dispute before reinstating it. Another seven states cover some weight loss drugs but specifically exclude GLP-1 injectables, offering only older or oral medications. If you’re on Medicaid, contact your state program directly to find out what’s currently covered, because the list changes frequently.
When Your Insurance Says No
A denial isn’t always the final answer. You have the right to appeal, and your doctor can submit additional documentation supporting medical necessity. If your plan covers weight loss injections but denied your specific request, the most common reasons are incomplete prior authorization paperwork, not meeting the BMI threshold at the time of the request, or not having documented a previous weight management attempt.
If your plan simply doesn’t include weight loss drugs on its formulary, an appeal is unlikely to succeed. In that case, your options are more limited. Manufacturer savings programs exist for Wegovy and Zepbound, but they are typically designed for people who already have commercial insurance coverage for the drug and want to reduce their copay. If your plan excludes the medication entirely, manufacturer coupons often don’t apply. Without any insurance coverage, these injections cost roughly $1,000 to $1,300 per month at retail price.
Some people switch to a plan that offers coverage during open enrollment. If weight loss medication is a priority for you, check formularies before choosing a plan. You can usually find this information on the insurer’s website or by calling member services.